BioPharm America™ 2013 program leads with plenary on drug development pipeline “The Chameleon Rubik’s Cube”
EBD Group’s BioPharm America™, hosted by MassBio, will kick off its 2013 program with an Opening Plenary entitled “Strategic R&D Planning: The Chameleon Rubik’s Cube” on Tuesday, September 17. The plenary features moderator Vaughn Kailian, Managing Director of MPM Capital and includes speakers James Hoyes, President of EMD Serono; David Meeker, CEO of Genzyme; and Roger Pomerantz, Senior VP and Head, Worldwide Licensing and Acquisitions at Merck. The panel will discuss long-term pipeline planning in drug development which can be likened to a Rubik’s cube that changes colors with its surroundings.
Other highlights of the 2013 program include a new spin on a conference favorite, Doug MacDougall’s “The Perfect Pitch: Do you have what it takes to win over investors?” and the workshop “Why can't big pharma invest in my company?” moderated by David Collier, CEO of Velocity Pharmaceutical Development.
“This year we have changed the program to include a full afternoon of roundtable discussions to engage conference attendees as well as the executive panelists,” said Carola Schropp, President of EBD Group. “The new roundtable format will promote discussion and interaction among discussion leaders and audience members, and therefore provide yet another networking opportunity for participants.”
Parallel roundtable discussions fall into four tracks:
- The future of dealmaking;
- External and internal drivers;
- Therapeutic spotlight; and
- Welcome to the digital age.
Sixteen roundtables are scheduled. An example is “Partnering: Thinking beyond the deal,” featuring Stephane Bancel, President and Founding CEO at Moderna Therapeutics; Christoph Pittius, VP, Strategic Partnering and Business Development, Cardiovascular/Metabolic at AstraZeneca; Jason Rhodes, Executive VP and CFO at Epizyme, Inc.; Ed Saltzman, President at Defined Health; and Andrew J. Schwab, Managing Partner at 5AM Ventures discussing the drivers for dealmaking with the audience.
EBD Group, the leading partnering firm for the life science industry, produces BioPharm America in collaboration with the Massachusetts Biotechnology Council (MassBio). It will be held in Boston September 17–19 at theWestin Boston Waterfront. The bio-pharma partnering event will welcome executives from big pharma, including AstraZeneca, Bayer HealthCare, EMD Serono, Janssen, Merck, Novo Nordisk, and Shire seeking to identify and enter into strategic relationships at the global level.
BioPharm America 2012 welcomed over 750 delegates representing 462 companies from 30 countries. Delegates in 2012 engaged in 1,846 one-to-one partnering meetings with 652 licensing opportunities.
Register before July 19, 2013 to save USD 200 athttp://www.ebdgroup.com/bpa/registration/index.php. MassBio members receive an additional USD 200 discount by adding the code ‘MassBio’ in the comments field of the online registration form.
Presenting companies should submit an application by June 28, 2013 athttp://www.ebdgroup.com/bpa/presenters/index.php